DECIPHEX LIMITED

Their core work

Deciphex develops artificial intelligence software for digital pathology — automating the analysis of tissue slides for clinical diagnostics and pharmaceutical safety testing. They apply machine learning to microscopy images, helping pathologists work faster and more accurately in both hospital and drug development settings. Their work spans from clinical GI (gastrointestinal) diagnostics to toxicological pathology for pharmaceutical companies, and they contribute to building Europe's central infrastructure for digital pathology data.

What they specialise in

How they've shifted over time

Deciphex began in 2017 with a small SME Phase 1 feasibility study (PATHOLYTIX-GI, €50K) validating their AI approach to clinical pathology. By 2018 they had moved into pharmaceutical applications with PATH-TOX (€1.6M), and by 2021 they joined BIGPICTURE (€2.45M), one of Europe's flagship digital pathology infrastructure projects. The trajectory shows a clear scaling pattern: from validating a product idea, to applying it in drug safety, to contributing to continent-wide pathology data infrastructure.

Deciphex is moving from niche AI pathology tools toward becoming a key technology provider for European-scale digital pathology data platforms and repositories.

How they like to work

Deciphex started as a coordinator on their small feasibility project (PATHOLYTIX-GI) but transitioned to a participant role in larger, well-funded consortia. With 53 unique partners across just 3 projects, their network is dominated by the large BIGPICTURE consortium, suggesting they operate as a specialized technology contributor within big collaborative efforts. This profile indicates they bring focused AI/pathology expertise to large teams rather than leading consortia themselves.

Despite only 3 projects, Deciphex has worked with 53 unique partners across 13 countries, primarily driven by the large BIGPICTURE consortium. Their network spans much of Europe, reflecting the broad, multi-country nature of major health data infrastructure initiatives.

What sets them apart

Deciphex sits at the intersection of artificial intelligence and pathology — a niche that few European SMEs occupy with real product experience. Their progression from a €50K feasibility study to a €2.45M role in BIGPICTURE demonstrates that larger consortia trust their technology in production-grade settings. For consortium builders, they offer a rare combination: an agile SME with hands-on AI pathology software, proven in both clinical and pharmaceutical contexts.

Highlights from their portfolio

• BIGPICTURE
  Largest project by funding (€2.45M to Deciphex), building Europe's central digital pathology repository — a flagship initiative running through 2027.
• PATHOLYTIX-GI
  Their origin project as coordinator — an SME Phase 1 that validated the AI pathology concept and launched the company's EU project trajectory.
• PATH-TOX
  Bridges AI pathology into pharmaceutical drug safety testing, demonstrating cross-domain applicability beyond clinical diagnostics.